Bhutani, M., Robinson, M., Foureau, D., Atrash, S., Paul, B., Guo, F., . . . Usmani, S. Z. MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma. Elsevier.
Chicago Style (17th ed.) CitationBhutani, Manisha, et al. MRD-driven Phase 2 Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma. Elsevier.
MLA (9th ed.) CitationBhutani, Manisha, et al. MRD-driven Phase 2 Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma. Elsevier.
Warning: These citations may not always be 100% accurate.